Last updated on July 2019

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With No Curative First-Line Treatment Option Recurrent or Refractory Solid Tumors And Primary Cns Tumors With or Without Trk Ros1 or Alk Fusions


Brief description of study

This is a 5-part, open-label, Phase 1/2 multicenter, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; 4) non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1 or ALK gene rearrangements; and 5) patients who are otherwise eligible but unable to swallow capsules. The study is designed to explore the safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetics, and antitumor activity of entrectinib.

Clinical Study Identifier: NCT02650401

Find a site near you

Start Over

Primary Children's Hospital

Salt Lake City, UT United States
  Connect »

Oregon Health & Science Uni

Portland, OR United States
  Connect »

Rady Childrens Hospital

San Diego, CA United States
  Connect »

Cook Childrens Medical Center

Fort Worth, TX United States
  Connect »

Johns Hopkins University

Baltimore, MD United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.